According to a new research report “Cyclin-Dependent Kinase (CDK) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, ad Other Developments” published by Pharma Proff, CDK inhibitors currently exhibit a proliferating pipeline with 10+ therapeutic candidates.
CDK Inhibitors Pipeline Insights
CDKs are protein kinases that require a separate subunit – a cyclin – which provides domains essential for enzymatic activity. The CDK family can be categorized into three cell-cycle-related subfamilies (CDK1, CDK4, and CDK5) and five transcriptional subfamilies (CDK7, CDK8, CDK9, CDK11, and CDK20). These protein kinases play a key role in controlling cell division and modulating transcription. Moreover, dysregulation of CDKs has been linked to cancer initiation and progression. Therefore, pharmacological CDK inhibition has emerged as a novel and promising approach in cancer therapy.
The CDK inhibitors are proteins that constrain the activities of CDKs. These proteins can be broadly classified into CDK1, CDK2, CDK4, CDK5, and CDK6. The primarily function of CDK inhibitors is to block the proliferation of cells by blocking the G1 phase of cell cycle.
Some of the approved CDK inhibitors include Verzenio (Eli Lilly and Company), Kisqali (Novartis AG), and Ibrance (Pfizer Inc.)
Insights into Pipeline Segments
According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered through oral route. It has been found that the oral route of administration is easy to use, patient compliant, and does not require much support.
Positive Clinical Results Play a Pivotal Role in CDK Inhibitors Development
There are several companies that are involved in developing CDK inhibitors have shown positive clinical results in various phases of drug development. For instance, Cyclacel Pharmaceuticals Inc. announced results of the phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a CDK2/9 inhibitor, in patients with advanced cancers. As per the results of the trial, CYC065 demonstrated effectiveness in suppressing the cancer survival protein Mcl-1 in peripheral blood for at least 24 hours. Therefore, it was concluded that the drug was safe and well tolerated.
Strategic Advancements Boost the Development of CDK Inhibitors
In the wake of strategic developments, MEI Pharma Inc. entered into a license agreement with Presage Biosciences Inc. for voruciclib, a clinical-stage, oral and selective CDK inhibitor. As per the terms of the agreement, MEI Pharma Inc. received exclusive worldwide rights to develop, manufacture, and commercialize voruciclib. In return, Presage Biosciences Inc. received near-term payments of $2.9 million and additional potential payments of up to $181 million upon the achievement of certain development, regulatory, and commercial milestones. In addition, Presage Biosciences Inc. is also subjected to receive mid-single-digit tiered royalties on the net sales of any product successfully developed.
Browse Detailed Report at:https://www.pharmaproff.com/report/cdk-inhibitors-therapeutics-pipeline-analysis
Eli Lilly and Company, Novartis AG, Pfizer Inc., MEI Pharma Inc., Cyclacel Pharmaceuticals Inc., Merck & Co., Tiziana Life Sciences, Onconova Therapeutics, Novartis International AG, and AstraZeneca plc are some of companies developing CDK inhibitors.
CDK Inhibitors Pipeline Analysis
The report comprises detailed pipeline analysis of CDK inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of CDK inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to CDK inhibitors.